[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615253":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":27,"centralContacts":31,"locations":36,"responsibleParty":53,"collaborators":57,"id":61,"slug":21,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":21,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":38,"whyStopped":21,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Remimazolam+Pain","EXPERIMENTAL","Single-arm study. All subjects receive remimazolam and painful electric nerve stimulation, while being imaged with MRI, as described in the interventions.",[13,14],"Drug: Remimazolam","Device: Peripheral Nerve Stimulation",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Remimazolam","Subjects in this group will receive an intravenous infusion of this drug, during a portion of the study.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DEVICE","Peripheral Nerve Stimulation","Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.",[9],[28],{"name":29,"affiliation":5,"role":30},"Keith M Vogt, MD, PhD","PRINCIPAL_INVESTIGATOR",[32],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":35},"CONTACT","4126473147","kev18@pitt.edu",[37],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Pittsburgh","Pennsylvania","15213","United States",{"type":44,"coordinates":45},"Point",[46,47],-79.99589,40.44062,{"lat":47,"lon":46},[50,51],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":35},{"name":52,"role":30,"phone":21,"phoneExt":21,"email":21},"Keith M. Vogt, MD, PhD",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"SPONSOR_INVESTIGATOR","Keith M Vogt","Associate Professor",[58],{"name":59,"class":60},"National Institute of General Medical Sciences (NIGMS)","NIH","100615253",false,"NCT07290205","Remimazolam NeuroImaging","Neuroimaging of Sedation With Remimazolam","REMAZ","Inclusion Criteria:\n\n* Adults 18-59 years of age, who:\n* have none of the specific exclusion criteria\n* have a valid email address and valid phone number throughout the study\n* free from any non-MRI compatible implants\n\nExclusion Criteria:\n\n* are pregnant or attempting to conceive\n* body mass index (BMI) \\> 35\n* significant memory impairment or hearing loss\n* sleep apnea\n* chronic pain or frequently taking pain medication (including tramadol)\n* chronic medical conditions requiring treatment (hypertension, diabetes, high cholesterol)\n* neurologic disease, including seizures and tremor\n* psychiatric diagnoses, including anxiety, depression, panic, or PTSD\n* a history of any of these medical conditions: abnormal heartbeats (cardiac conduction abnormality or arrhythmia), liver or kidney disease, or significant lung disease\n* severe claustrophobia or MRI intolerance\n* have metal implants or non-removable metal piercings\n* having a history of adverse reaction to midazolam (Versed), lorazepam (Ativan) or another benzodiazepine class medication\n* are allergic to dextran\n* daily alcohol or heavy alcohol use; history of alcohol abuse\n* current daily smoker\n* regular or recent marijuana use (including prescribed\u002Fmedical marijuana)\n* illicit drug use, i.e., street drugs\n* regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids",true,"ALL","18 Years","59 Years",{"count":73,"type":74},60,"ESTIMATED","INTERVENTIONAL",[77],"EARLY_PHASE1","This is a single-arm functional MRI study that will determine the effects of remimazolam on cognition and brain activity and connectivity at rest, during noxious stimulation, and during a memory encoding task",[80,81,18],"Anesthesia","Pain",[18,83,84,85,86,87,88],"functional MRI","electric nerve stimulation","sedation","functional connectivity","memory","pain","2026-03-27",{"date":91,"type":92},"2026-04-02","ACTUAL",{"date":89,"type":92},{"date":95,"type":74},"2027-12-02",{"name":55,"class":6},1]